February 17, 2021
MRVL Pet Pharmaceuticals has hired Panacea Life Sciences to re-formulate the
Blue Scorpion CTX Pet Immune Support and Joint Support both with and
without CBD pet line in a palatable liquid formulation and will be available as early as May 1st, 2021.   
MRVL Pet Pharmaceuticals has hired Altran, part of Capgemini, as the team to provide advisory services for regulatory affairs and compliance testing for the development and submission of animal health drugs containing the Blue Scorpion CTX.  The goal is to submit a New Animal Drug Application to the Center for Veterinary Medicine trials for drug approval for canine and feline arthritis and cancer. Ms. Deborah Cenci is the Project Manager and Regulatory Lead along with Dr. Albert Ahn as consultant.


December 10, 2020

MRVL Pet Pharmaceuticals  is pleased to announce that Dr. Joel Navratik will be joining the team as President & CEO. Dr. Navratik brings valuable knowledge and talent to MRVL Pet Pharmaceuticals  with her extensive background in veterinary care and veterinary clinics.